Skip to content

3D glasses may improve adherence to treatment in Glaucoma patients that use only one eyedrop. A clinical study.

3D virtual reality may enhance adherence in glaucoma patients using monotherapy - a randomized clinical trial - 3D: Third Dimension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-5zcggj
Enrollment
Unknown
Registered
2019-06-04
Start date
2017-04-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Experimental group: 35 patients with glaucoma, watch an 8-minute-video, which provides information regarding glaucoma and its consequences. The video is realistic and simulates the real sight loss of
Device
L01.224.160.875

Sponsors

HCloe Clinica Oftalmológica Especializada
Lead Sponsor
HCloe Clinica Oftalmológica Especializada
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: We included glaucoma patients with age equal to or above 18; who were already being treated at our clinics; with the minimal visual acuity 20/40 according to the Snellen table

Exclusion criteria

Exclusion criteria: The exclusion criteria included an age of fewer than 18-years-old; the demand for surgery during the three-month evaluation period; corneal diseases that interfered with the accurate measurement of intraocular pressure (IOP); retinal diseases that impeded the quality of an optical tomography coherence exam (OCT) and computer perimetry.

Design outcomes

Primary

MeasureTime frame
We seek to find a difference in intraocular pressure (IOP) reduction, after 3-month treatment, between 3D and control group, in favor of the 3D group in the average of 1.5 mmHg, from the average of three consecutive measurements in Goldman's tonometer.

Secondary

MeasureTime frame
We seek to find significant differences in the measurements of the visual field, pachimetry and optical coherence tomography between both 3D and control groups, in the range of 5% between the groups. We applied a Topcon DRI – Triton for pachimetry and OCT measurements, and Achromatic Perimetry Visual Field Humphrey 2 – 740 central 24-2 White White

Countries

Brazil

Contacts

Public ContactRegina Cele Seixas

HCloe Clinica Oftalmológica Especializada

reginacele@uol.com.br11-??99124-6070

Outcome results

None listed

Source: REBEC (via WHO ICTRP)